{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:31:34Z","timestamp":1786984294026,"version":"build-2736575974"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"33","license":[{"start":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:00:00Z","timestamp":1786665600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Project of Youth Science and Technology of Medical Science Research in Hebei Province","award":["20201574"],"award-info":[{"award-number":["20201574"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,8,14]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>\n                      This study explores the association between tumor necrosis factor (TNF) antagonist therapy and the progression from undifferentiated arthritis (UA) to rheumatoid arthritis (RA). This single-center prospective observational real-world study enrolled 70 patients with UA (baseline score\u2005\u2265\u20058) at Xingtai People\u2019s Hospital (May\u2013December 2020). After propensity score matching (1:1), 64 patients were matched; 4 lost to follow-up were excluded, leaving 60 for final analysis. Patients received MTX monotherapy or etanercept\u2005+\u2005MTX. Between-group differences were assessed using the Mann\u2013Whitney\n                      <jats:italic toggle=\"yes\">U<\/jats:italic>\n                      test, chi-square test, or Fisher exact test. Survival was analyzed using Kaplan\u2013Meier curves and log-rank tests, and independent prognostic factors were identified through multivariable Cox regression. A total of 60 patients (30 per group) were included in the final analysis. During the 3-year follow-up, patients in the etanercept\u2005+\u2005MTX group had a significantly lower risk of progression to RA compared with the MTX monotherapy group (6\/30 [20.0%] vs 14\/30 [46.7%]; log-rank\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u2005.012). After adjusting for potential confounders, combination therapy remained independently associated with reduced progression risk (HR\u2005=\u20050.28, 95% CI: 0.10\u20130.83,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u2005.022). Clinical remission at 3 years was achieved in 25 of 30 patients (83.3%) in the combination group, compared to 17 of 30 (56.7%) in the monotherapy group (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u2005.024). In this exploratory real-world observational study, initial treatment with etanercept\u2005+\u2005MTX was associated with a lower observed risk of progression to RA and a higher observed rate of clinical remission than MTX monotherapy in high-risk UA patients. These findings should be considered hypothesis-generating and require confirmation in adequately powered randomized controlled trials in diverse populations.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000050284","type":"journal-article","created":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T18:02:39Z","timestamp":1786730559000},"page":"e50284","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Impact of etanercept on the progression of undifferentiated arthritis to rheumatoid arthritis"],"prefix":"10.1097","volume":"105","author":[{"given":"Jingfang","family":"Shen","sequence":"first","affiliation":[{"name":"Department of Rheumatology, Xingtai People\u2019s Hospital, Xingtai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lianju","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Xingtai People\u2019s Hospital, Xingtai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoli","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Xingtai People\u2019s Hospital, Xingtai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Leng","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Xingtai People\u2019s Hospital, Xingtai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangzhuo","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Xingtai People\u2019s Hospital, Xingtai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6689-5722","authenticated-orcid":false,"given":"Junfeng","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Neurology, Xingtai People\u2019s Hospital, Xingtai, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260817","doi-asserted-by":"crossref","first-page":"3212","DOI":"10.1093\/rheumatology\/keab880","article-title":"Undifferentiated arthritis: a changing population who did not benefit from enhanced disease-modifying anti-rheumatic drug strategies-results from a 25\u2009year longitudinal inception cohort.","volume":"61","author":"Verstappen","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"R2-20260817","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1136\/ard.2009.119016","article-title":"Impact of T-cell costimulation modulation in patients with undifferentiated inflammatory arthritis or very early rheumatoid arthritis: a clinical and imaging study of abatacept (the ADJUST trial).","volume":"69","author":"Emery","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"R3-20260817","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41413-018-0016-9","article-title":"Rheumatoid arthritis: pathological mechanisms and modern pharmacologic therapies.","volume":"6","author":"Guo","year":"2018","journal-title":"Bone Res"},{"key":"R4-20260817","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1016\/S0140-6736(23)01525-8","article-title":"Rheumatoid arthritis.","volume":"402","author":"Di Matteo","year":"2023","journal-title":"Lancet"},{"key":"R5-20260817","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1136\/annrheumdis-2019-216716","article-title":"The earlier, the better or the worse? Towards accurate management of patients with arthralgia at risk for RA.","volume":"79","author":"van der Helm-van Mil","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"R6-20260817","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1136\/ard.2007.084269","article-title":"Does the use of tumour necrosis factor antagonist therapy in poor prognosis, undifferentiated arthritis prevent progression to rheumatoid arthritis?","volume":"67","author":"Saleem","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"R7-20260817","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1136\/ard.2009.122473","article-title":"The Stop Arthritis Very Early (SAVE) trial, an international multicentre, randomised, double-blind, placebo-controlled trial on glucocorticoids in very early arthritis.","volume":"69","author":"Machold","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"R8-20260817","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1136\/ard.2009.119149","article-title":"Beneficial effects of a 3-week course of intramuscular glucocorticoid injections in patients with very early inflammatory polyarthritis: results of the STIVEA trial.","volume":"69","author":"Verstappen","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"R9-20260817","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1136\/annrheumdis-2012-202967","article-title":"Five-year outcomes of probable rheumatoid arthritis treated with methotrexate or placebo during the first year (the PROMPT study).","volume":"73","author":"van Aken","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"R10-20260817","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1002\/art.41589","article-title":"Etanercept or methotrexate withdrawal in rheumatoid arthritis patients in sustained remission.","volume":"73","author":"Curtis","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"R11-20260817","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/s40744-020-00211-w","article-title":"Biologic disease-modifying antirheumatic drug prescription patterns among rheumatologists in Europe and Japan.","volume":"7","author":"Sullivan","year":"2020","journal-title":"Rheumatol Ther"},{"key":"R12-20260817","doi-asserted-by":"crossref","first-page":"139","DOI":"10.2147\/OARRR.S282627","article-title":"Current and emerging DMARDs for the treatment of rheumatoid arthritis.","volume":"13","author":"Mysler","year":"2021","journal-title":"Open Access Rheumatol"},{"key":"R13-20260817","first-page":"e58112","article-title":"The role of etanercept in controlling clinical and radiological progression in rheumatoid arthritis: a systematic review.","volume":"16","author":"Ejaz","year":"2024","journal-title":"Cureus"},{"key":"R14-20260817","doi-asserted-by":"crossref","first-page":"99","DOI":"10.2147\/tcrm.2007.3.1.99","article-title":"Etanercept in the treatment of rheumatoid arthritis.","volume":"3","author":"Haraoui","year":"2007","journal-title":"Ther Clin Risk Manag"},{"key":"R15-20260817","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1093\/rheumatology\/kez518","article-title":"Early response to anti-TNF predicts long-term outcomes including sustained remission: an analysis of the BSRBR-RA.","volume":"59","author":"Hamann","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"R16-20260817","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/ard-2022-223356","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update.","volume":"82","author":"Smolen","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"R17-20260817","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.ard.2025.01.042","article-title":"Predictors of arthritis development in individuals at risk of rheumatoid arthritis: a 5-year follow-up study from a large cohort.","volume":"84","author":"Frazzei","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"R18-20260817","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1002\/art.22380","article-title":"A prediction rule for disease outcome in patients with recent-onset undifferentiated arthritis: how to guide individual treatment decisions.","volume":"56","author":"van der Helm-van Mil","year":"2007","journal-title":"Arthritis Rheum"},{"key":"R19-20260817","doi-asserted-by":"crossref","first-page":"268","DOI":"10.7326\/M16-2607","article-title":"Sensitivity analysis in observational research: introducing the E-value.","volume":"167","author":"VanderWeele","year":"2017","journal-title":"Ann Intern Med"},{"key":"R20-20260817","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1136\/annrheumdis-2017-212612","article-title":"Ability of disease-modifying antirheumatic drugs to prevent or delay rheumatoid arthritis onset: a systematic literature review and meta-analysis.","volume":"77","author":"Hilliquin","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"R21-20260817","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/S0140-6736(23)02649-1","article-title":"Abatacept in individuals at high risk of rheumatoid arthritis (APIPPRA): a randomised, double-blind, multicentre, parallel, placebo-controlled, phase 2b clinical trial.","volume":"403","author":"Cope","year":"2024","journal-title":"Lancet"},{"key":"R22-20260817","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1136\/annrheumdis-2012-203165","article-title":"Drug therapy in undifferentiated arthritis: a systematic literature review.","volume":"72","author":"Wevers-de Boer","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"R23-20260817","doi-asserted-by":"crossref","first-page":"e000186","DOI":"10.1136\/rmdopen-2015-000186","article-title":"Efficacy of etanercept in combination with methotrexate in moderate-to-severe rheumatoid arthritis is not dependent on methotrexate dosage.","volume":"2","author":"Gallo","year":"2016","journal-title":"RMD Open"},{"key":"R24-20260817","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1002\/acr.22638","article-title":"Etanercept-methotrexate combination therapy initiators have greater adherence and persistence than triple therapy initiators with rheumatoid arthritis.","volume":"67","author":"Bonafede","year":"2015","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R25-20260817","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1186\/s13075-018-1667-z","article-title":"Induction of sustained remission in early inflammatory arthritis with the combination of infliximab plus methotrexate: the DINORA trial.","volume":"20","author":"Stamm","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"R26-20260817","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1136\/annrheumdis-2013-203284","article-title":"Performance of the 2010 ACR\/EULAR classification criteria for rheumatoid arthritis: a systematic literature review.","volume":"73","author":"Radner","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"R27-20260817","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1136\/annrheumdis-2013-203402","article-title":"Long-term outcome of rheumatoid arthritis defined according to the 2010-classification criteria.","volume":"73","author":"Burgers","year":"2014","journal-title":"Ann Rheum Dis"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000050284","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:01:37Z","timestamp":1786982497000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000050284"}},"subtitle":["A prospective observational study in China"],"short-title":[],"issued":{"date-parts":[[2026,8,14]]},"references-count":27,"journal-issue":{"issue":"33","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000050284","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,14]]},"assertion":[{"value":"2026-01-12","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-03","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}